Caldera Therapeutics, Inc.
Last verified 2026-05-06. JSON
| Total raised | $37.5M |
|---|---|
| Latest round | Funding round, $37.5M, 2026-01-08 |
| Founded | 2025 |
| Headquarters | Cambridge, Massachusetts |
| Industry | biotechnology |
| Stage | unknown |
| Website | calderatx.com |
Caldera Therapeutics is a clinical-stage biotech developing the first-in-class bispecific antibody CLD-423 for inflammatory bowel disease and other inflammatory conditions. It targets patients and clinicians facing IBD that has plateaued on single-target therapies. Its differentiator is hitting two validated pathways, IL-23p19 and TL1A, in one molecule.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-01-08 | Funding round | $37.5M | undisclosed |
Detected tech stack
Typekit, Adobe Fonts, Afterpay, Sentry, Spin.js, Squarespace, Squarespace Commerce, Stimulus, parallax.js, web-vitals, moment 0, @sentry/browser
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $37.5M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $37.5M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | calderatx.com, read 2026-05-06 |
| Description | self-reported | calderatx.com, read 2026-05-06 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $37.5M, 2026-01-08 → Funding round, $37.5M, 2026-01-08, SEC EDGAR, document, retrieved 2026-09-25 | Latest round | seed, $37.5M, 2026-01-08 → Funding round, $37.5M, 2026-01-08 | SEC EDGAR, document, retrieved 2026-09-25 |
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes